Switch theme
Sign up to access all valuation multiples
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
1997
322
LTM Revenue $252M
LTM EBITDA $145M
$728M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cosmo Pharmaceuticals has a last 12-month revenue of $252M and a last 12-month EBITDA of $145M.
In the most recent fiscal year, Cosmo Pharmaceuticals achieved revenue of $302M and an EBITDA of $187M.
Cosmo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cosmo Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $105M | $302M | XXX | XXX | XXX |
| Gross Profit | $94.2M | $83.6M | XXX | XXX | XXX |
| Gross Margin | 90% | 28% | XXX | XXX | XXX |
| EBITDA | $27.5M | $187M | XXX | XXX | XXX |
| EBITDA Margin | 26% | 62% | XXX | XXX | XXX |
| Net Profit | $19.5M | -$5.6M | XXX | XXX | XXX |
| Net Margin | 19% | -2% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cosmo Pharmaceuticals's stock price is CHF 48 (or $55).
Cosmo Pharmaceuticals has current market cap of CHF 774M (or $876M), and EV of CHF 644M (or $728M).
See Cosmo Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $728M | $876M | XXX | XXX | XXX | XXX | $7.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cosmo Pharmaceuticals has market cap of $876M and EV of $728M.
Cosmo Pharmaceuticals's trades at 2.7x LTM EV/Revenue multiple, and 4.8x LTM EBITDA.
Analysts estimate Cosmo Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cosmo Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $728M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 3.9x | XXX | XXX | XXX |
| P/E | 5.8x | XXX | XXX | XXX |
| P/E/Growth | -0.1x | XXX | XXX | XXX |
| EV/FCF | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCosmo Pharmaceuticals's NTM/LTM revenue growth is -30%
Cosmo Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Cosmo Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cosmo Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cosmo Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 188% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 62% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 581% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cosmo Pharmaceuticals acquired XXX companies to date.
Last acquisition by Cosmo Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Cosmo Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cosmo Pharmaceuticals founded? | Cosmo Pharmaceuticals was founded in 1997. |
| Where is Cosmo Pharmaceuticals headquartered? | Cosmo Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Cosmo Pharmaceuticals have? | As of today, Cosmo Pharmaceuticals has 322 employees. |
| Who is the CEO of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's CEO is Mr. Giovanni Di Napoli. |
| Is Cosmo Pharmaceuticals publicy listed? | Yes, Cosmo Pharmaceuticals is a public company listed on SWX. |
| What is the stock symbol of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals trades under COPN ticker. |
| When did Cosmo Pharmaceuticals go public? | Cosmo Pharmaceuticals went public in 2007. |
| Who are competitors of Cosmo Pharmaceuticals? | Similar companies to Cosmo Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's current market cap is $876M |
| What is the current revenue of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's last 12-month revenue is $252M. |
| What is the current EBITDA of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's last 12-month EBITDA is $145M. |
| What is the current EV/Revenue multiple of Cosmo Pharmaceuticals? | Current revenue multiple of Cosmo Pharmaceuticals is 2.7x. |
| What is the current EV/EBITDA multiple of Cosmo Pharmaceuticals? | Current EBITDA multiple of Cosmo Pharmaceuticals is 4.8x. |
| What is the current revenue growth of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals revenue growth between 2023 and 2024 was 188%. |
| Is Cosmo Pharmaceuticals profitable? | Yes, Cosmo Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
